IMMUNOVANT, INC. Operating Cash Flow
IMMUNOVANT, INC. (IMVT) reported Operating Cash Flow of -$124.41 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-06
- IMMUNOVANT, INC. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$124.41M.
- IMMUNOVANT, INC. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$95.06M.
- IMMUNOVANT, INC. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$92.33M.
- IMMUNOVANT, INC. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$102.52M.
- IMMUNOVANT, INC. net cash provided by (used in) operating activities for fiscal 2026 was -$407.31M.
- IMMUNOVANT, INC. net cash provided by (used in) operating activities for fiscal 2025 was -$375.87M.
- IMMUNOVANT, INC. net cash provided by (used in) operating activities for fiscal 2024 was -$214.23M.
- IMMUNOVANT, INC. net cash provided by (used in) operating activities for fiscal 2023 was -$188.19M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$124.41M 10-Q · filed 2026-08-06 | -$219.46M derived: sum of 2 quarters · filed 2026-08-06 | -$311.79M derived: sum of 3 quarters · filed 2026-08-06 | -$414.30M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$95.06M derived: 10-K 12 month − 10-Q 9 month · filed 2026-05-20 | -$187.38M derived: sum of 2 quarters · filed 2026-05-20 | -$289.90M derived: sum of 3 quarters · filed 2026-05-20 | -$407.31M 10-K · filed 2026-05-20 |
| 2025-12-31 | -$92.33M derived: 10-Q 9 month − 10-Q 6 month · filed 2026-02-06 | -$194.84M derived: sum of 2 quarters · filed 2026-02-06 | -$312.25M 10-Q · filed 2026-02-06 | -$422.89M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-09-30 | -$102.52M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-11-10 | -$219.93M 10-Q · filed 2025-11-10 | -$330.56M derived: sum of 3 quarters · filed 2026-08-06 | -$430.95M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$117.41M 10-Q · filed 2026-08-06 | -$228.05M derived: sum of 2 quarters · filed 2026-08-06 | -$328.44M derived: sum of 3 quarters · filed 2026-08-06 | -$417.09M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$110.64M derived: 10-K 12 month − 10-Q 9 month · filed 2026-05-20 | -$211.03M derived: sum of 2 quarters · filed 2026-05-20 | -$299.68M derived: sum of 3 quarters · filed 2026-05-20 | -$375.87M 10-K · filed 2026-05-20 |
| 2024-12-31 | -$100.39M derived: 10-Q 9 month − 10-Q 6 month · filed 2026-02-06 | -$189.04M derived: sum of 2 quarters · filed 2026-02-06 | -$265.24M 10-Q · filed 2026-02-06 | -$324.94M derived: sum of 4 quarters · filed 2026-05-20 |
| 2024-09-30 | -$88.65M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-11-10 | -$164.85M 10-Q · filed 2025-11-10 | -$224.54M derived: sum of 3 quarters · filed 2026-05-20 | -$271.64M derived: sum of 4 quarters · filed 2026-05-20 |
| 2024-06-30 | -$76.20M 10-Q · filed 2025-08-11 | -$135.90M derived: sum of 2 quarters · filed 2026-05-20 | -$183.00M derived: sum of 3 quarters · filed 2026-05-20 | -$243.06M derived: sum of 4 quarters · filed 2026-05-20 |
| 2024-03-31 | -$59.70M derived: 10-K 12 month − 10-Q 9 month · filed 2026-05-20 | -$106.80M derived: sum of 2 quarters · filed 2026-05-20 | -$166.86M derived: sum of 3 quarters · filed 2026-05-20 | -$214.23M 10-K · filed 2026-05-20 |
| 2023-12-31 | -$47.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-02-06 | -$107.16M derived: sum of 2 quarters · filed 2025-02-06 | -$154.53M 10-Q · filed 2025-02-06 | -$210.32M derived: sum of 4 quarters · filed 2025-05-29 |
| 2023-09-30 | -$60.06M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-11-07 | -$107.43M 10-Q · filed 2024-11-07 | -$163.22M derived: sum of 3 quarters · filed 2025-05-29 | -$209.62M derived: sum of 4 quarters · filed 2025-05-29 |
| 2023-06-30 | -$47.37M 10-Q · filed 2024-08-06 | -$103.16M derived: sum of 2 quarters · filed 2025-05-29 | -$149.56M derived: sum of 3 quarters · filed 2025-05-29 | -$169.74M derived: sum of 4 quarters · filed 2025-05-29 |
| 2023-03-31 | -$55.79M derived: 10-K 12 month − 10-Q 9 month · filed 2025-05-29 | -$102.19M derived: sum of 2 quarters · filed 2025-05-29 | -$122.37M derived: sum of 3 quarters · filed 2025-05-29 | -$188.19M 10-K · filed 2025-05-29 |
| 2022-12-31 | -$46.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-02-12 | -$66.58M derived: sum of 2 quarters · filed 2024-02-12 | -$132.40M 10-Q · filed 2024-02-12 | -$165.36M derived: sum of 4 quarters · filed 2024-02-12 |
| 2022-09-30 | -$20.19M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-11-09 | -$86.00M 10-Q · filed 2023-11-09 | -$118.96M derived: sum of 3 quarters · filed 2023-11-09 | -$150.86M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | -$65.82M 10-Q · filed 2023-08-10 | -$98.78M derived: sum of 2 quarters · filed 2023-08-10 | -$130.67M derived: sum of 3 quarters · filed 2023-08-10 | -$150.72M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | -$32.96M derived: 10-K 12 month − 10-Q 9 month · filed 2023-05-22 | -$64.85M derived: sum of 2 quarters · filed 2023-05-22 | -$84.90M derived: sum of 3 quarters · filed 2023-05-22 | -$106.11M 10-K · filed 2023-05-22 |
| 2021-12-31 | -$31.89M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-02-03 | -$51.94M derived: sum of 2 quarters · filed 2023-02-03 | -$73.16M 10-Q · filed 2023-02-03 | -$95.65M derived: sum of 4 quarters · filed 2023-02-03 |
| 2021-09-30 | -$20.05M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-11-04 | -$41.26M 10-Q · filed 2022-11-04 | -$63.76M derived: sum of 3 quarters · filed 2022-11-04 | -$86.57M derived: sum of 4 quarters · filed 2022-11-04 |
| 2021-06-30 | -$21.21M 10-Q · filed 2022-08-05 | -$43.71M derived: sum of 2 quarters · filed 2022-08-05 | -$66.53M derived: sum of 3 quarters · filed 2022-08-05 | -$90.74M derived: sum of 4 quarters · filed 2022-08-05 |
| 2021-03-31 | -$22.50M derived: 10-K 12 month − 10-Q 9 month · filed 2022-06-08 | -$45.31M derived: sum of 2 quarters · filed 2022-06-08 | -$69.53M derived: sum of 3 quarters · filed 2022-06-08 | -$83.33M 10-K · filed 2022-06-08 |
| 2020-12-31 | -$22.82M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-02-04 | -$47.03M derived: sum of 2 quarters · filed 2022-02-04 | -$60.83M 10-Q · filed 2022-02-04 | -$83.88M derived: sum of 4 quarters · filed 2022-02-04 |
| 2020-09-30 | -$24.22M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-11-05 | -$38.02M 10-Q · filed 2021-11-05 | -$61.07M derived: sum of 3 quarters · filed 2021-11-05 | -$65.48M derived: sum of 4 quarters · filed 2021-11-05 |
| 2020-06-30 | -$13.80M 10-Q · filed 2021-08-09 | -$36.85M derived: sum of 2 quarters · filed 2021-08-09 | -$41.27M derived: sum of 3 quarters · filed 2021-08-09 | -$58.82M derived: sum of 4 quarters · filed 2021-08-09 |
| 2020-03-31 | -$23.05M derived: 10-K 12 month − 10-Q 9 month · filed 2021-06-01 | -$27.47M derived: sum of 2 quarters · filed 2021-06-01 | -$45.02M derived: sum of 3 quarters · filed 2021-06-01 | -$53.36M 10-K · filed 2021-06-01 |
| 2019-12-31 | -$4.42M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-02-16 | -$21.98M derived: sum of 2 quarters · filed 2021-02-16 | -$30.31M 10-Q · filed 2021-02-16 | -$30.31M derived: sum of 4 quarters · filed 2021-02-16 |
| 2019-09-30 | -$17.56M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-11-12 | -$25.89M 10-Q · filed 2020-11-12 | -$532.24K 10-Q · filed 2019-11-13 | |
| 2019-06-30 | -$8.33M 10-Q · filed 2020-08-12 | -$230.73K 10-Q · filed 2019-08-12 | ||
| 2019-03-31 | -$450.00 10-Q · filed 2019-06-12 | -$28.55M 10-K · filed 2020-06-29 | ||
| 2018-12-31 | -$15.90M 10-Q · filed 2020-02-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |